Hal Baseman
The Power List 2021 – Biopharmaceuticals
Chief Operating Officer at Valsource
“The global pandemic has resulted in the need to accelerate the development, approval, and distribution of COVID-19 related products. This need, combined with the complexities of manufacturing drug products during a time of pandemic related-restrictions, has uncovered areas where there are opportunities for improvement. This includes: risk- and science-based regulatory decision making to help companies and regulators prioritize and evaluate alternative and better means to control drug manufacturing processes; manufacturing supply reliability to ensure essential materials are available; expansion of capability to provide production lines for the manufacture of essential drug products; technical resources to develop and implement drug product manufacturing methods and technologies; and harmonization, modernization, and understanding of post-approval change procedures and requirements to provide the most valuable information needed for the expansion of drug product manufacturing output and reduce barriers to that expansion.”
